BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BIOCRATES Life Sciences GmbH Participates in 2.9 Million Euro EU Cancer Diagnostics Project


5/10/2007 1:41:49 PM

INNSBRUCK, Austria, May 10 /PRNewswire/ -- BIOCRATES life sciences will play a pivotal role in one of the latest framework six EU projects called COBRED. COBRED's participants will use innovative technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.

Each partner brings specific strengths to the project, creating a strong R&D collaboration. Biocrates' strengths lie in targeted metabolomics. Brad Morie, Chief Business Development Officer at Biocrates, said "This project comes at a perfect time for us. We have officially launched our proprietary targeted metabolomics services platform, TargetIDQ(TM). TargetIDQ(TM) has proven effective in our collaborations with pharmaceutical companies and helped us discover metabolic biomarkers. We plan to leverage TargetIDQ(TM) to identify and quantify over 1000 metabolites in the COBRED study, ultimately yielding novel cancer biomarkers."

Eight partners from France, Hungary, Estonia, and Austria will collaborate to discover biomarkers which assess the risk of cancer recurrences after initial tumor removal. Klaus Weinberger, Biocrates' CSO, explained, "COBRED provides an excellent platform for translational research because of the close interaction between the best clinical centers and analytical/technology partners. The overarching goal is to develop better means of cancer detection than current expensive and invasive diagnostic techniques."

Armin Graber, Biocrates' CEO, stated, "Our vision is to apply these novel treatments to a larger, population-based screening program. A successful outcome will ease the burden on social medicine programs, because early detection has proven to increase the efficacy of treatment and lower costs for all cancers."

About BIOCRATES life sciences GmbH

BIOCRATES is the leader in targeted metabolomics. We pioneered an integrated mass spectrometry based technology platform for extracting detailed information residing in metabolic networks with unprecedented speed and high confidence. We use a quantitative approach incorporating numerous internal standards enabling us to immediately identify metabolites, measure their absolute concentrations, and map them to their respective pathways. In addition, we are the only company offering a convenient, disposable kit covering several metabolite classes simultaneously. Our services, kits, and software set the standard for metabolomics in pharmaceutical research. We partner with the most innovative pharmaceutical, biotechnology, and nutritional companies to identify and validate new biomarkers, streamlining the drug development process and revolutionizing clinical diagnostics.

Dr. Klaus Weinberger CSO BIOCRATES life sciences +43-512-579823 klaus.weinberger@biocrates.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

BIOCRATES life sciences

CONTACT: Dr. Klaus Weinberger, CSO of BIOCRATES life sciences,+43-512-579823, or klaus.weinberger@biocrates.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES